Terms: = Astrocytoma AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Treatment
721 results:
1. C1GALT1 high expression enhances the progression of glioblastoma through the egfr-AKT/ERK cascade.
Su Y; Ao X; Long Y; Zhang Z; Zhang M; Zhang Z; Wei M; Shan S; Lu S; Yu Y; Xu B
Cell Signal; 2025 Jan; 125():111513. PubMed ID: 39561885
[TBL] [Abstract] [Full Text] [Related]
2. Stimuli-Responsive Peptide/siRNA Nanoparticles as a Radiation Sensitizer for Glioblastoma treatment by Co-Inhibiting RELA/P65 and egfr.
Cen B; Zhang J; Pan X; Xu Z; Li R; Chen C; Wang B; Li Z; Zhang G; Ji A; Yuan Y
Int J Nanomedicine; 2024; 19():11517-11537. PubMed ID: 39539970
[TBL] [Abstract] [Full Text] [Related]
3. Discovery of novel Macrocyclic small molecules Based on 2-Amino-4-thiazolylpyridineas selective egfr inhibitors with high Blood-Brain barrier penetration for the treatment of glioblastoma.
Wu G; Zhou M; Guo F; Lin Y; Chen Y; Kong Y; Xiao J; Wan S; Li Z; Wu X; Zhang T; Zhang J
Bioorg Chem; 2024 Dec; 153():107905. PubMed ID: 39476599
[TBL] [Abstract] [Full Text] [Related]
4. Novel strategies to overcome chemoresistance in human glioblastoma.
Tang Q; Ren T; Bai P; Wang X; Zhao L; Zhong R; Sun G
Biochem Pharmacol; 2024 Dec; 230(Pt 2):116588. PubMed ID: 39461382
[TBL] [Abstract] [Full Text] [Related]
5. The Large GTPase Guanylate-Binding Protein-1 (GBP-1) Promotes Mitochondrial Fission in Glioblastoma.
Kalb RC; Nyabuto GO; Morran MP; Maity S; Justinger JS; Nestor-Kalinoski AL; Vestal DJ
Int J Mol Sci; 2024 Oct; 25(20):. PubMed ID: 39457021
[TBL] [Abstract] [Full Text] [Related]
6. A pH-Sensitive cRGD-PEG-siRNA Conjugated Compound Targeting Glioblastoma.
Su Q; Chen J; Liu Z; Fan Y; He S
Bioconjug Chem; 2024 Nov; 35(11):1732-1743. PubMed ID: 39431993
[TBL] [Abstract] [Full Text] [Related]
7. Molecular Testing in Gliomas: What is Necessary in Routine Clinical Practice?
Alnahhas I
Curr Oncol Rep; 2024 Nov; 26(11):1277-1282. PubMed ID: 39361075
[TBL] [Abstract] [Full Text] [Related]
8. All-in-one bimodal DNA and RNA next-generation sequencing panel for integrative diagnosis of glioma.
Higa N; Akahane T; Kirishima M; Yonezawa H; Makino R; Uchida H; Yokoyama S; Takajo T; Otsuji R; Fujioka Y; Sangatsuda Y; Kuga D; Yamahata H; Hata N; Horie N; Kurosaki M; Yamamoto J; Yoshimoto K; Tanimoto A; Hanaya R
Pathol Res Pract; 2024 Nov; 263():155598. PubMed ID: 39357189
[TBL] [Abstract] [Full Text] [Related]
9. Prospective Molecular Targets for Natural Killer Cell Immunotherapy against Glioblastoma Multiforme.
Cooksey LC; Friesen DC; Mangan ED; Mathew PA
Cells; 2024 Sep; 13(18):. PubMed ID: 39329751
[TBL] [Abstract] [Full Text] [Related]
10. The role of molecular biomarkers in recurrent glioblastoma trials: an assessment of the current trial landscape of genome-driven oncology.
van Opijnen MP; de Vos FYF; Cuppen E; Geurts M; Maas SLN; Broekman MLD
Med Oncol; 2024 Sep; 41(11):250. PubMed ID: 39316248
[TBL] [Abstract] [Full Text] [Related]
11. Glioma nanotherapy: Unleashing the synergy of dual-loaded DIM and TMZ.
Sarkar S; Kumar S; Saha G; Basu M; Ghosh MK
Int J Pharm; 2024 Nov; 665():124697. PubMed ID: 39270762
[TBL] [Abstract] [Full Text] [Related]
12. Chromosomal instability: a key driver in glioma pathogenesis and progression.
Mazzoleni A; Awuah WA; Sanker V; Bharadwaj HR; Aderinto N; Tan JK; Huang HYR; Poornaselvan J; Shah MH; Atallah O; Tawfik A; Elmanzalawi MEAE; Ghozlan SH; Abdul-Rahman T; Moyondafoluwa JA; Alexiou A; Papadakis M
Eur J Med Res; 2024 Sep; 29(1):451. PubMed ID: 39227895
[TBL] [Abstract] [Full Text] [Related]
13. Importance of Autophagy Regulation in Glioblastoma with Temozolomide Resistance.
Hwang YK; Lee DH; Lee EC; Oh JS
Cells; 2024 Aug; 13(16):. PubMed ID: 39195222
[TBL] [Abstract] [Full Text] [Related]
14. 5-Aminolevulinic acid-mediated photodynamic therapy in combination with kinase inhibitor lapatinib enhances glioblastoma cell death.
Chandratre S; Merenich D; Myers K; Chen B
Apoptosis; 2024 Dec; 29(11-12):1978-1987. PubMed ID: 39190205
[TBL] [Abstract] [Full Text] [Related]
15. Kinetic Trajectories of Glucose Uptake in Single Cancer Cells Reveal a Drug-Induced Cell-State Change Within Hours of Drug treatment.
Kim J; Ng RH; Liang J; Johnson D; Shin YS; Chatziioannou AF; Phelps ME; Wei W; Levine RD; Heath JR
J Phys Chem B; 2024 Aug; 128(33):7978-7986. PubMed ID: 39115241
[TBL] [Abstract] [Full Text] [Related]
16. Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis.
Guo G; Zhang Z; Zhang J; Wang D; Xu S; Liu G; Gao Y; Mei J; Yan Z; Zhao R; Wang M; Li T; Bu X
Cancer Immunol Immunother; 2024 Aug; 73(10):193. PubMed ID: 39105794
[TBL] [Abstract] [Full Text] [Related]
17. Genomics and proteomics to determine novel molecular subtypes and predict the response to immunotherapy and the effect of bevacizumab in glioblastoma.
Luo D; Luo A; Hu S; Ye G; Li D; Zhao H; Peng B
Sci Rep; 2024 Jul; 14(1):17630. PubMed ID: 39085480
[TBL] [Abstract] [Full Text] [Related]
18. Discovery of a Therapeutic Agent for Glioblastoma Using a Systems Biology-Based Drug Repositioning Approach.
Kaynar A; Ozcan M; Li X; Turkez H; Zhang C; Uhlén M; Shoaie S; Mardinoglu A
Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063109
[TBL] [Abstract] [Full Text] [Related]
19. A syngeneic spontaneous zebrafish model of
Weiss A; D'Amata C; Pearson BJ; Hayes MN
Elife; 2024 Jul; 13():. PubMed ID: 39052000
[TBL] [Abstract] [Full Text] [Related]
20. Mutations in glioblastoma proteins do not disrupt epitope presentation and recognition, maintaining a specific CD8 T cell immune response potential.
Tarabini RF; Fioravanti Vieira G; Rigo MM; de Souza APD
Sci Rep; 2024 Jul; 14(1):16721. PubMed ID: 39030304
[TBL] [Abstract] [Full Text] [Related]
[Next]
